Table 3.

Simulated average dose of lenvatinib and proportion of patients with ≥ 1 dose reduction due to an adverse event during 24 weeks of treatment

Lenvatinib dosing regimen (mg)	Average dose (mg/day)	Patients with dose reductions (%)
		≥ 1	≥ 2	≥ 3	≥ 4
Without up-titration
24	19.23	68.5	33.8	11.2	2.7
20	16.09	60.8	22.3	5.4	1.2
18	15.13	57.3	20.8	5.4	1.2
14	12.15	46.9	12.3	2.7	0.4
With up-titration
20	18.35	67.7	30.4	8.1	1.9
18	17.90	67.7	28.1	7.7	1.9
14	16.90	65.4	23.8	5.0	0.8